At NMD Pharma, we’re committed to discovering and developing innovative new medicines for serious neuromuscular diseases.

Sometimes, patients may wish to access investigational medicines that are not yet approved by the U.S. Food and Drug Administration (FDA).

At this time NMD Pharma does not have an Expanded Access program for our development programs in spinal muscular atrophy, myasthenia gravis and Charcot Marie Tooth disease.

We anticipate providing Expanded Access within certain countries to our investigational drug, NMD670, when we have results from our phase 3 clinical trials that indicate NMD670 may provide benefit for patients with acceptable safety.

Currently, the most appropriate way patients could access NMD670 is through participation in our phase 2 clinical trials. Overseen by a team of medical experts, these clinical trials are designed to determine whether an investigational medicine is safe and effective for patients. More information on our clinical development programs in spinal muscular atrophy (NCT05794139), myasthenia gravis (NCT06414954) and Charcot Marie Tooth disease (NCT06482437) can be found at https://clinicaltrials.gov/

We encourage patients to discuss with their healthcare providers if participation in one of our planned or ongoing clinical trials is appropriate. If you have any questions about our clinical trial programs or individual clinical trials, please contact us at contact@nmdpharma.com